STOCK TITAN

Baxter International Inc. - BAX STOCK NEWS

Welcome to our dedicated news page for Baxter International (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baxter International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baxter International's position in the market.

Rhea-AI Summary
Baxter International Inc. announces new data indicating that its Sharesource remote patient management platform is associated with a 77% reduction in risk of peritoneal dialysis technique failure. Additionally, the HDx therapy enabled by Theranova dialyzer can help reduce water consumption by 27% and electricity usage by 17% compared to hemodiafiltration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary
Baxter International Inc. reported third-quarter revenue of $3.71 billion, a 3% increase on a reported basis and 2% increase on a constant currency basis. The company's adjusted EPS from continuing operations was $0.68, exceeding guidance. Baxter has implemented a new operating model with four verticalized business segments. The company completed the divestiture of its BioPharma Solutions business and is progressing with the planned spinoff of its Kidney Care segment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
earnings
-
Rhea-AI Summary
Baxter International launches digital image capture capability for eye exams
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
Rhea-AI Summary
Baxter International appoints Joel Grade as CFO, effective Oct. 18, 2023. Brian Stevens transitions to prior role. Grade brings decades of experience from Sysco. Positive impact expected on growth, innovation, and value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
management
-
Rhea-AI Summary
Advent International and Warburg Pincus complete the acquisition of Baxter International's BioPharma Solutions business, which will now operate as Simtra BioPharma Solutions. Baxter received $4.25 billion in cash. Simtra will continue to offer contract manufacturing solutions and support services to the pharmaceutical and biotech industries. The company plans to expand its drug development offering and capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
acquisition
-
Rhea-AI Summary
Baxter International Inc. to discuss Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences earnings
Rhea-AI Summary
Baxter International to present at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Summary
Advent International and Warburg Pincus select Franco Negron as CEO of BioPharma Solutions following its divestiture from Baxter International Inc. The closing of the divestiture is expected to occur in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Baxter International Inc. to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
Rhea-AI Summary
Baxter International appoints Stephen H. Rusckowski to its board of directors and announces the resignation of Michael Mahoney.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
management
Baxter International Inc.

NYSE:BAX

BAX Rankings

BAX Stock Data

21.77B
505.48M
0.38%
92.37%
1.61%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Deerfield

About BAX

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.